News
NIH awards US$24m for maternal health research centres of excellence
The centres aim to develop and evaluate innovative approaches to reduce pregnancy-related complications and deaths
The National Institutes of Health has awarded US$24m in first-year funding to establish maternal health research centres of excellence.
Part of NIH’s Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone (IMPROVE) initiative, the centres will develop and evaluate innovative approaches to reduce pregnancy-related complications and deaths and promote maternal health equity.
The grants are expected to last seven years and total an estimated US$168m, pending the availability of funds.
Compared to other high-income countries, the US has a high rate of maternal deaths, with more than 1,200 such deaths occurring in 2021, the most recent year for which data are available.
Each year tens of thousands more Americans experience severe pregnancy-related complications, which can raise the risk of future health concerns, including high blood pressure, diabetes and mental health conditions.
There are stark disparities in these maternal health outcomes by racial and ethnic group, age, education, socioeconomic status and geographic region.
“The magnitude and persistence of maternal health disparities in the United States underscore the need for research to identify evidence-based solutions to promote health equity and improve outcomes nationwide,” said Diana W. Bianchi, director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
“Through collaborations with community partners and others, the maternal health research centres of excellence will generate critical scientific evidence to help guide clinical care and reduce health disparities during and after pregnancy.”
NICHD, the NIH Office of Research on Women’s Health and the National Institute of Nursing Research co-lead the IMPROVE initiative, with involvement from several other components at NIH.
The centres of excellence include 10 research centres, a data innovation and coordinating hub and an implementation science hub. Together, these institutions aim to work to design and implement research projects to address the biological, behavioural, environmental, sociocultural and structural factors that affect pregnancy-related complications and deaths.
According to the NIH, they will focus on populations that experience health disparities, including racial and ethnic minorities, socioeconomically disadvantaged populations, those living in underserved rural areas, sexual and gender minority populations and people with disabilities.
Research centres will partner with community collaborators, such as state and local public health agencies, community health centres and faith-based organisations.
Additionally, the NIH says they will support training and professional development of maternal health researchers, including those from backgrounds underrepresented in the biomedical research workforce.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






